Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017
INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomised, double-blind, placebo-controlled trial, have been presented as part of ......

